Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Fulvia D'Elia"'
Autor:
Antonino Guerrisi, Emiliano Loi, Sara Ungania, Michelangelo Russillo, Vicente Bruzzaniti, Fulvia Elia, Flora Desiderio, Raffaella Marconi, Francesco Maria Solivetti, Lidia Strigari
Publikováno v:
Cancer Medicine, Vol 9, Iss 5, Pp 1603-1612 (2020)
Abstract Advanced malignant melanoma represents a public health matter due to its rising incidence and aggressiveness. Novel therapies such as immunotherapy are showing promising results with improved progression free and overall survival in melanoma
Externí odkaz:
https://doaj.org/article/701ac65c6f894042901c52aedb5ed154
Autor:
Marinella Tedesco, Valentina Garelli, Fulvia Elia, Francesca Sperati, F. Biondi, L. Mosiello, Aldo Morrone, Emilia Migliano
Publikováno v:
Journal of Cosmetic Dermatology. 22:449-457
Lichen Sclerosus is a chronic-relapsing inflammatory skin disease which involves most commonly the anogenital region. The gold standard in treatment is ultra-potent topical steroids (clobetasol propionate): it aims at controlling the symptoms, stoppi
Autor:
Fulvia Elia, Vicente Bruzzaniti, Sara Ungania, Lidia Strigari, Flora Desiderio, F. M. Solivetti, Michelangelo Russillo, Raffaella Marconi, Emiliano Loi, Antonino Guerrisi
Publikováno v:
Cancer Medicine, Vol 9, Iss 5, Pp 1603-1612 (2020)
Cancer Medicine
Cancer Medicine
Advanced malignant melanoma represents a public health matter due to its rising incidence and aggressiveness. Novel therapies such as immunotherapy are showing promising results with improved progression free and overall survival in melanoma patients
Autor:
Marinella Tedesco, Valentina Garelli, Fulvia Elia, Francesca Sperati, Aldo Morrone, Emilia Migliano
Publikováno v:
Dermatologic therapyREFERENCES. 35(4)
Lichen Sclerosus is a chronic-relapsing inflammatory skin disease usually involving the anogenital region lacking a resolutive therapy. Potent to high-potent topical corticosteroids are considered to be the standard first-line treatment. The objectiv
Autor:
Luca Fania, Giulia Giovanardi, Tonia Samela, Dante Caposiena, Andrea Chiricozzi, Flaminia Antonelli, Pierluigi Saraceni, Fulvia Elia, Simone Garcovich, Davide Ciccone, Maria Vittoria Cannizzaro, Emanuele Miraglia, Chiara Iacovino, Sandra Giustini, Nevena Skroza, Alessandra Mambrin, Concetta Potenza, Luca Bianchi, Ketty Peris, Damiano Abeni
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 14; Pages: 4037
Adalimumab is the only biologic agent approved for the treatment of moderate-to-severe hidradenitis suppurativa (HS) patients (i.e., with Hurley II or III), which is recommended in two different maintenance doses (i.e., 40 mg weekly or 80 mg every tw
AB0563 DISCONTINUATION OF ANTI-TNFα IN PATIENTS WITH PSORIATIC ARTHRITIS: A SINGLE-CENTER EXPERIENCE
Publikováno v:
Annals of the Rheumatic Diseases. 80:1318.1-1318
Background:TNF inhibitors have been largely demonstrated to be effective and reasonably safe for the treatment of psoriatic arthritis (PsA). Current EULAR guidelines recommend the use of an anti-TNF as first choice treatment in patients with PsA for
Publikováno v:
International journal of dermatologyReferences. 58(12)
Sebaceous cysts are benign enveloped nodules resulting from an obstruction of a hair follicle. Although they are very common, differential diagnosis is not obvious and may include many diseases. Ultrasound examination with high frequency probes, in t
Autor:
Fulvia D'Elia
Publikováno v:
MINORIGIUSTIZIA. :156-165
Our results indicate that ATT could represent a useful paraclinic method in identifying CFs in subjects at risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d77800d37097af27bc7800c94b0d2d
Autor:
Fulvia D'Elia
Publikováno v:
MINORIGIUSTIZIA. :37-41